About us
Core development
RepoCeuticals’ strategy is to reposition, reroute, and recombine natural agents for new prophylactic and therapeutic uses for reducing the significant and severe side effects of radiotherapy and cytotoxic therapy in treatment of cancer, and for new therapeutic uses for relieving the devastating symptoms and chronic consequences of low anterior resection syndrome.
Repositioning
Repositioning is a new use for an established therapeutic agent. This entails registration and using the agent for a different indication i.e. treating another condition than its previous registered use.
Rerouting
Rerouting is changing the route of administration of the active ingredient to one that is suitable for the new indication. RepoCeuticals formulates the active ingredients to suit local administration at the specific physical site where they need to act. This dramatically improves the efficiency of the active ingredient, which reaches the site of action at high concentration while avoiding conventional systemic administration e.g. by intravenous and subcutaneous injection, thus reducing any systemic adverse reactions.
Combining
Combining different active substances that act in different ways to achieve an additive or synergistic effect. The best generally applicable combination is developed for a given indication, so that the patient and the clinician do not have to use several different medications to treat a single condition.
Management
-
Torsten Bjørn CEOSolid background in mechanical engineering.
Involved with several pharmaceutical companies which were subsequently sold to industry buyers or went public through an IPO.
Torsten Bjørn has been responsible for accounting (ÅRL / IFRS), budgeting, financial calculations, consolidation of subsidiaries, internal controlling and reporting in Reponex as well as several other companies.
-
Lars Otto Uttenthal CSO
Professor Dr. Uttenthal is a former researcher at the Universities of Oxford, London and Madrid and was Professor in Biochemistry at the University of Salamanca.
He has over 45 years of experience in clinical medicine and biomedical research, as well as 18 years’ experience in directing R&D in the medical industry.
Dr. Uttenthal also has extensive experience with the conception of new patent applications and seeing them through the examination process.
Board Members
-
Søren Nielsen Executive Board Member
MD, dr.med., former professor at the Universities of Aarhus University and Aalborg University and associated with National Institutes of Health, USA and Johns Hopkins University Medical School, USA
Søren Nielsen now serves as CEO of AKI Therapeutics A/S and as executive chairman of the board of directors of RepoCeuticals A/S. Søren Nielsen also serves as board member of additional biotech companies.
Co-founder and director of Action Pharma A/S (2001-2010 as CEO and 2010-2012 as COO).
-
Troels Peter Troelsen Board Member
Troels Peter Troelsen is chairman of the board in 6 companies.
He has over 17 years of experience as CEO of larger companies and over 17 years of experience as Associate Professor at the Copenhagen Business School (CBS).
Troels Peter Troelsen has participated in 3 stock listings (IPO’s) at Nasdaq OMX Copenhagen.
-
Henrik Bulskov Board Member
Specialised in Orphan Diseases and Orphan Legislation.
Obtain approval of 4 OD designation in US and EUWorked within the Pharmaceutical industri for more that 25 years – in different companies and different positions.
Experience within Hematology, Oncology, Infectious Diseases, COPD and CF, Cardiovascular Diseases and others.
-
Christian Vinding Thomsen Board Member
Christian Vinding Thomsen has 20+ years of experience and is specialised within Regulatory Life Science, Healthcare, M&A and Corporate Law.
Christian also highly specialised in legal issues facing the pharmaceutical industry, and has represented multiple companies in issues such as GCP, GMP, GDP, Market Access and Marketing Compliance.
Team leader in multiple large successful transactions including listings and mergers within the pharmaceutical industry.
-
Charlotte Pahl Board Member
Charlotte Pahl, Director at Sobi AB, Global Medical Affairs, Hematology.
She has over 30 years of experience in the pharmaceutical industry gained while working for Sobi.
Charlotte Pahl has a wide range of international contacts and networks within the healthcare business, healthcare professionals and patients’ organisations.
Scientific Advisory Board
-
Peter Agre Scientific Advisor
Professor Peter Agre, MD, is a Bloomberg distinguished professor at Johns Hopkins University, Baltimore, MD, USA.
Professor Peter Agre received the Nobel prize in 2003 in chemistry for his discovery of aquaporin water channels for their fundamental roles in human health and disease.
Professor Peter Agre has expertise in molecular biology, biochemistry, cell biology, structural biology and physiology/pathophysiology.
-
Simon C. Robson Scientific Advisor
Professor Simon C. Robson, MB, ChB, FRCP, FAASLD, PhD, Harvard Medical School, Boston, MA, USA.
Professor Simon Robson is Professor of Anaesthesia and Charlotte F. & Irving W. Rabb Distinguished Professor of Gastroenterology and Hepatology, Vice Chair of Research, Department of Anesthesia, Critical Care and Pain Medicine, and Director of the Center for Inflammation Research.
Professor Robson’s research areas are basic science, translational research, inflammation, vascular biology, immunity and immunometabolism.
